<DOC>
	<DOCNO>NCT01623102</DOCNO>
	<brief_summary>Advanced non-small-cell lung cancer ( NSCLC ) patient without epidermal growth factor receptor ( EGFR ) mutation show poor prognosis . Gemcitabine combine cisplatin chemotherapy effective treatment measure EGFR mutation-negative NSCLC patient , prognosis remain poor . Chemotherapy combine targeted monoclonal antibody treatment may better treatment option patient . Monoclonal antibody , bevacizumab , block tumor growth different way . Bevacizumab block ability tumor grow new blood vessel spread . It yet know whether cisplatin gemcitabine effective give alone bevacizumab . This randomized trial study well give cisplatin gemcitabine alone combination Bevacizumab ( Avastin ) work treat patient stage IIIB/IV non-squamous NSCLC without EGFR mutation .</brief_summary>
	<brief_title>Cisplatin Gemcitabine With Without Bevacizumab EGFR Wild-type Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Lung cancer lead cause cancer morbidity mortality worldwide . The majority lung cancer nonsquamous NSCLC . EGFR tyrosine kinase inhibitor ( EGFR-TKI ) effective first-line treatment EGFR mutation non-squamous NSCLC treatment . But patient without epidermal growth factor receptor ( EGFR ) mutation show poor prognosis . Gemcitabine combine cisplatin chemotherapy effective treatment measure EGFR mutation-negative NSCLC patient , prognosis remain poor . Chemotherapy combine targeted monoclonal antibody treatment may better treatment option patient . Monoclonal antibody , bevacizumab , block tumor growth different way . Bevacizumab block ability tumor grow new blood vessel spread . This randomized trial study well give cisplatin gemcitabine alone combination Bevacizumab ( Avastin ) work treat patient stage IIIB/IV non-squamous NSCLC without EGFR mutation . Accordingly , come scientific hypothesis cisplatin gemcitabine combination Bevacizumab might better treatment strategy stage IIIB/IV non-squamous NSCLC patient EGFR wild-type . It improve PFS stage IIIB/IV non-squamous NSCLC patient EGFR wild-type . The primary endpoint disease-free time progression ( PFS ) . The secondary study endpoint objective response rate ( ORR ) , disease control rate ( DCR ) , safety quality life ( QOL ) . Through study lay foundation exploration non-squamous NSCLC first-line treatment patient EGFR wild-type strategy , guide rational application bevacizumab .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologic documentation primary lung carcinoma , nonsquamous histology EGFR mutation Negative . Stage IIIB/IV disease accord 7th Edition American Joint Committee Cancer stag system Not receive radiotherapy , chemotherapy biological treatment Measureable disease Life expectancy &gt; = 12 month Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Absolute neutrophil count ( ANC ) &gt; = 2 , 500/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 9.0 g/dL Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamic pyruvic transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) = &lt; 2.5 x ULN patient without liver bone metastasis ; &lt; 5 x ULN patient liver bone metastasis CockcroftGault calculate creatinine clearance &gt; = 45 ml/min creatinine = &lt; 1.5 x ULN Prothrombin time ( PT ) = &lt; 1.5 x ULN Partial thromboplastin time ( PTT ) = &lt; ULN Urine dipstick proteinuria &lt; 2+ * Note : Patients discover &gt; = 2 + proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate &lt; 1 g protein 24 hour Negative pregnancy test do = &lt; 7 day prior randomization , woman childbearing potential Provide inform write consent Willing return Sichuan cancer hospital followup Willing provide tissue blood sample correlative research purpose Mixed , nonsmall cell small cell tumor mix adenosquamous carcinoma predominant squamous component Prior chemotherapy treatment metastatic nonsmall cell lung cancer Immunocompromised patient ( relate use corticosteroid ) include patient know human immunodeficiency virus ( HIV ) positive , per MD discretion Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Receiving investigational agent would consider treatment primary neoplasm Other active malignancy = &lt; 3 year prior randomization ; EXCEPTIONS : Non melanotic skin cancer carcinomainsitu cervix History myocardial infarction evidence arterial thrombotic disease ( angina ) History cerebral vascular accident ( CVA ) transient ischemic attack ( TIA ) = &lt; 6 month prior randomization Ongoing active infection , symptomatic congestive heart failure , cardiac arrhythmia , psychiatric illness/social situation , medical condition would limit compliance study requirement History bleed diathesis coagulopathy Inadequately control hypertension ( systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 100 mmHg antihypertensive medication ) Serious nonhealing wound , ulcer , bone fracture , undergone major surgical procedure , open biopsy , significant traumatic injury = &lt; 28 day core biopsy = &lt; 7 day prior randomization History abdominal fistula , gastrointestinal perforation , intrabdominal abscess = &lt; 6 month prior randomization History hemoptysis &gt; = grade 2 ( define bright red blood least 2.5 mL ) = &lt; 3 month prior randomization Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Bevacizumab</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>cisplatin</keyword>
	<keyword>EGFR wild-type</keyword>
</DOC>